First Pharmacological Therapy for Hypoactive Sexual Desire Disorder in Premenopausal Women: Flibanserin.
Robinson K, Cutler JB, Carris NW.
Ann Pharmacother · review; journal article · DOI 10.1177/1060028015622182 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för flibanserin. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
17 träffarFlibanserin-Stimulated Partner Grooming Reflects Brain Metabolism Changes in Female Marmosets.
Converse AK, Aubert Y, Allers KA, Sommer B, Abbott DH.
J Sex Med · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1111/jsm.13068Sex drive and sexual desire.
Holloway V, Wylie K.
Curr Opin Psychiatry · review; journal article · DOI 10.1097/yco.0000000000000199The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.
Kingsberg SA, Clayton AH, Pfaus JG.
CNS Drugs · review; journal article · DOI 10.1007/s40263-015-0288-1Addendum: Flibanserin (Addyi) for hypoactive sexual desire disorder.
Författaruppgift saknas
Med Lett Drugs Ther · journal articleTreatment for hypoactive sexual desire.
Pfaus JG.
Cell · journal article · DOI 10.1016/j.cell.2015.10.015U.S. Food and Drug Administration Approval of Addyi (Flibanserin) for Treatment of Hypoactive Sexual Desire Disorder.
Puppo G, Puppo V.
Eur Urol · letter · DOI 10.1016/j.eururo.2015.09.050Flibanserin: First Global Approval.
Deeks ED.
Drugs · review; journal article · DOI 10.1007/s40265-015-0474-yPharmaceutical Approval Update.
Gohil K.
P T · research-article; journal articleFlibanserin (Addyi) for hypoactive sexual desire disorder.
Författaruppgift saknas
Med Lett Drugs Ther · review; journal articleFlibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.
Dhanuka I, Simon JA.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2015.1090426Why are there no FDA-approved treatments for female sexual dysfunction?
Nappi RE.
Expert Opin Pharmacother · editorial · DOI 10.1517/14656566.2015.1064393Hypoactive sexual desire disorder: inventing a disease to sell low libido.
Meixel A, Yanchar E, Fugh-Berman A.
J Med Ethics · journal article · DOI 10.1136/medethics-2014-102596Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder.
Stahl SM.
CNS Spectr · review; journal article · DOI 10.1017/s1092852914000832Flibanserin for female sexual dysfunction.
Reviriego C.
Drugs Today (Barc) · journal article · DOI 10.1358/dot.2014.50.8.2198036Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial.
Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M, Sand M.
Menopause · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1097/gme.0000000000000134Determination of flibanserin and tadalafil in supplements for women sexual desire enhancement using high-performance liquid chromatography with tandem mass spectrometer, diode array detector and charged aerosol detector.
Poplawska M, Blazewicz A, Zolek P, Fijalek Z.
J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2014.01.021